Collaborative network of predictive markers complicates formation of prognostic groups in patients with advanced lung cancer.

Background: Evaluation of cancer therapies is mainly based on prolonging remission status and effect of survival. Various serological, clinical or histological markers are used to estimate the patient's prognosis, and to tailor specific therapies for patients with poor prognosis. However, it is still a challenge to combine all this information into a comprehensive risk prediction.